Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Neha Mehta-Shah,Steven Horwitz,Pier Luigi Zinzani,Stefan K Barta,Makoto Yamagishi,David M Kurtz,Gensuke Takayama,Yoshiyuki Hizukuri,Weiguo Feng,Ken C N Chang,Takaya Moriyama,Keiko Nakajima,Ai Inoue,Emmanuel Bachy

doi:10.1182/blood-2024-207594

Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Neha Mehta-Shah, Steven Horwitz + Show 12 more

https://doi.org/10.1182/blood-2024-207594

Copy DOI

Export

Save

Cite

Journal: Blood

Publication Date: Nov 5, 2024

#Prediction Of Clinical Response #Peripheral T-Cell Lymphoma #Phased Variants #Circulating Tumor DNA #Refractory Peripheral T-Cell Lymphoma #Refractory Lymphoma #Prediction Of Response #Tumor DNA #T-Cell Lymphoma #Clinical Response

Abstract
Full-Text
Similar Papers

Abstract

Listen

Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)